|Bid||45.33 x 1000|
|Ask||45.37 x 800|
|Day's Range||45.07 - 46.16|
|52 Week Range||34.00 - 63.00|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 06, 2023 - Nov 10, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||74.14|
Subscribe to Yahoo Finance Plus to view Fair Value for NTRA
AUSTIN, Texas, September 18, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced three appointments within its senior leadership team, effective immediately.
An in-depth look at Natera Inc's valuation and financial performance
AUSTIN, Texas, September 14, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap Healthcare Collaborative, that will use Signatera, Natera’s personalized and tumor-informed molecular residual disease (MRD) test, to monitor response to neoadjuvant therapy in breast cancer patients across all subtypes.